Arctic Bioscience AS (BST:9TD)

Market Cap	5.77M -22.0%
Revenue (ttm)	4.33M +6.7%
Net Income	-3.54M
EPS	-0.14
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	0.1845
Previous Close	0.1615
Day's Range	0.1515 - 0.1940
52-Week Range	0.0832 - 0.3560
Beta	n/a
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 10, 2026

About Arctic Bioscience AS

Arctic Bioscience AS, a clinical-stage biotechnology company, engages in developing and commercializing pharmaceutical and nutraceutical ingredients based on bioactive marine compounds in Norway, the United States, Europe, and Asia Pacific. The company is developing HRO350, a novel oral drug which is in phase IIb for the treatment of mild-to-moderate psoriasis; and the HeROPA study, an international phase IIb clinical trial. It also sells nutraceuticals as an intermediary and finished goods products under the ROMEGA brand name. Arctic Bioscienc...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2011
• Employees: 19
• Stock Exchange: Stuttgart Stock Exchange
• Ticker Symbol: 9TD

Financial Performance

In 2025, Arctic Bioscience AS's revenue was 42.62 million, a decrease of -4.00% compared to the previous year's 44.39 million. Losses were -41.03 million, -14.41% less than in 2024.

Financial numbers in NOK

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Oct 31, 2026

Data Sources Report a data error